Breaking News

Northstar Medical Radioisotopes, Nucleus Radiopharma Ink Supply Pact

NorthStar’s high purity non-carrier-added Ac-225 to be used in advancing customers radioligand therapies to treat cancer.

NorthStar Medical Radioisotopes, LLC, a global developer and producer of radiopharmaceuticals used for therapeutic applications and medical imaging, and Nucleus RadioPharma, a contract development and manufacturing organization (CDMO) dedicated to building robust and reliable clinical and commercial supply chains for targeted radiotherapies, signed a supply agreement for the therapeutic radioisotope actinium-225 (Ac-225). NorthStar will supply its high purity, non-carrier added (n.c.a.) Ac-225 t...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters